ES2127484T3 - Sistema matricial transdermico autoadhesivo para la administracion por via percutanea de una hormona. - Google Patents

Sistema matricial transdermico autoadhesivo para la administracion por via percutanea de una hormona.

Info

Publication number
ES2127484T3
ES2127484T3 ES95400573T ES95400573T ES2127484T3 ES 2127484 T3 ES2127484 T3 ES 2127484T3 ES 95400573 T ES95400573 T ES 95400573T ES 95400573 T ES95400573 T ES 95400573T ES 2127484 T3 ES2127484 T3 ES 2127484T3
Authority
ES
Spain
Prior art keywords
transdermic
self
hormone
parts
adhesive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95400573T
Other languages
English (en)
Inventor
Eric Teillaud
Antoine Sawaya
Marie-Christine Math
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires dHygiene et de Dietetique SA
Original Assignee
Laboratoires dHygiene et de Dietetique SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires dHygiene et de Dietetique SA filed Critical Laboratoires dHygiene et de Dietetique SA
Application granted granted Critical
Publication of ES2127484T3 publication Critical patent/ES2127484T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN NUEVO SISTEMA MATRICIAL TRANSDERMICO AUTOADHESIVO PARA LA ADMINISTRACION POR VIA PERCUTANEA DE UNA HORMONA, CARACTERIZANDOSE DICHO SISTEMA, QUE COMPRENDE UN SOPORTE Y UNA MATRIZ AUTOADHESIVA, EN QUE DICHA MATRIZ COMPRENDE (A) 40 A 60 PARTES EN PESO DE COPOLIMERO DE ETILENO Y DE ACETATO DE VINILO, (B) 5 A 20 PARTES EN PESO DE DERIVADO DE CELULOSA, (C) 35 A 55 PARTES EN PESO DE LA MENOS UN COMPUESTO ELEGIDO ENTRE - EL CROTAMITON, - LAS 2.PIRROLIDONAS N-SUSTITUIDAS DE FORMULA I DONDE R REPRESENTA UN GRUPO ALKILO EN C1-C15, EL GRUPO CICLOHEXILO O EL GRUPO 2-HIDROCIETILO, Y LOS ALCOHOLES ALIFATICVOS SUPERIORES EN C12-C20, Y D) 0,01 A 7 PARTES EN PESO DE UNA HORMONA ELEGIDA ENTRE EL CONJUNTO CONSTITUIDO POR LOS COMPONENTES ESTROGENOS, LOS COMPONENTES PROGESTATIVOS Y SUS MEZCLAS. SE REFIERE TAMBIEN A UN PROCESO PARA LA PREPARACION DE ESTE SISTEMA MATERIAL TRANSDERMICO.
ES95400573T 1994-03-28 1995-03-15 Sistema matricial transdermico autoadhesivo para la administracion por via percutanea de una hormona. Expired - Lifetime ES2127484T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9403598A FR2717688B1 (fr) 1994-03-28 1994-03-28 Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA.

Publications (1)

Publication Number Publication Date
ES2127484T3 true ES2127484T3 (es) 1999-04-16

Family

ID=9461478

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95400573T Expired - Lifetime ES2127484T3 (es) 1994-03-28 1995-03-15 Sistema matricial transdermico autoadhesivo para la administracion por via percutanea de una hormona.

Country Status (23)

Country Link
US (1) US5605702A (es)
EP (1) EP0674900B1 (es)
JP (1) JPH07309762A (es)
KR (1) KR950031056A (es)
CN (1) CN1114587A (es)
AT (1) ATE173617T1 (es)
AU (1) AU684601B2 (es)
CA (1) CA2145579A1 (es)
CZ (1) CZ289211B6 (es)
DE (1) DE69506156T2 (es)
DK (1) DK0674900T3 (es)
ES (1) ES2127484T3 (es)
FI (1) FI951425A7 (es)
FR (1) FR2717688B1 (es)
GR (1) GR3029402T3 (es)
HU (1) HU219245B (es)
LV (1) LV10930B (es)
NO (1) NO308124B1 (es)
NZ (1) NZ270810A (es)
PL (1) PL179022B1 (es)
RU (1) RU2144818C1 (es)
SK (1) SK281234B6 (es)
ZA (1) ZA952468B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0394429B1 (de) * 1988-10-27 1996-01-10 Schering Aktiengesellschaft Mittel zur transdermalen applikation enthaltend gestoden
KR970706805A (ko) * 1994-11-18 1997-12-01 나까토미 히로타카 경피흡수첩부제(percutaneously absorbable patch)
FR2739032B1 (fr) * 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base d'eva, procede de preparation et utilisation en therapeutique
DE69734060T2 (de) 1996-05-24 2006-06-29 Angiotech Pharmaceuticals, Inc., Vancouver Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
US5783208A (en) * 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
DE19700913C2 (de) * 1997-01-14 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Hormonen
IL123813A0 (en) * 1997-04-11 1998-10-30 Akzo Nobel Nv Drug delivery system for two or more active substances
US6028057A (en) * 1998-02-19 2000-02-22 Thorn Bioscience, Llc Regulation of estrus and ovulation in gilts
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
DE10025970C2 (de) * 2000-05-25 2002-04-25 Lohmann Therapie Syst Lts Estrogenhaltiges Pflaster mit einem Wirkstoffreservoir auf der Basis von Ethylcellulose und einem Ethylen-Vinylacetat-Vinylpyrrolidon-Copolymer und seine Verwendung
DE10118282A1 (de) * 2001-04-12 2002-12-05 Lohmann Therapie Syst Lts Haftkleber auf Basis von Ethylen-Vinylacetat-Copolymeren und Klebharzen, für medizinische Verwendungszwecke
DE602004026173D1 (de) * 2003-04-29 2010-05-06 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
WO2005035717A2 (en) 2003-10-03 2005-04-21 Thorn Bioscience, Llc Process for the synchronization of ovulation for timed breeding without heat detection
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US20070197435A1 (en) * 2006-02-17 2007-08-23 Webel Stephen K Process for the synchronization of ovulation for timed breeding without heat detection
PE20081140A1 (es) * 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
RU2568839C2 (ru) 2009-04-23 2015-11-20 ДжейБиЭс Юнайтид Энимал Хэлс II ЛЛК Способ и композиция для синхронизации времени осеменения
PH12013501865A1 (en) 2011-03-16 2014-01-06 Amgen Inc Potent and selective inhibitors of nav1.3 and nav1.7
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
EP2925339B1 (en) 2012-11-28 2020-04-29 United-AH II, LLC Method for synchronizing time of insemination in gilts
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4060084A (en) * 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4752612A (en) * 1983-07-01 1988-06-21 Nitto Electrical Industrial Co., Ltd. Method and percutaneously administering physiologically active agents using an alcohol adjuvant and a solvent
FR2612785A1 (fr) * 1987-03-25 1988-09-30 Lhd Lab Hygiene Dietetique Dispositif auto-adhesif d'administration d'un principe actif par voie percutanee
US4994267A (en) * 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5032402A (en) * 1988-10-27 1991-07-16 The University Of Kentucky Research Foundation 3-hydroxy-N-methylpyrrolidone and use as transdermal enhancer
CA2004203A1 (en) * 1988-12-01 1990-06-01 Sharad K. Govil Compositions for transdermal delivery of estradiol
US5248676A (en) * 1990-05-17 1993-09-28 Hisamitsu Pharmaceutical Co., Inc. Estradiol percutaneous administration preparations

Also Published As

Publication number Publication date
HU9500881D0 (en) 1995-05-29
SK281234B6 (sk) 2001-01-18
FI951425A0 (fi) 1995-03-24
HUT75237A (en) 1997-05-28
EP0674900A1 (fr) 1995-10-04
NO951125D0 (no) 1995-03-24
GR3029402T3 (en) 1999-05-28
KR950031056A (ko) 1995-12-18
NZ270810A (en) 1996-05-28
AU1497995A (en) 1995-10-05
FR2717688A1 (fr) 1995-09-29
AU684601B2 (en) 1997-12-18
LV10930B (en) 1996-08-20
PL307889A1 (en) 1995-10-02
EP0674900B1 (fr) 1998-11-25
RU2144818C1 (ru) 2000-01-27
NO308124B1 (no) 2000-07-31
PL179022B1 (en) 2000-07-31
FI951425A7 (fi) 1995-09-29
LV10930A (lv) 1995-12-20
CA2145579A1 (en) 1995-09-29
CZ76895A3 (en) 1995-10-18
DK0674900T3 (da) 1999-06-23
US5605702A (en) 1997-02-25
HU219245B (en) 2001-03-28
ZA952468B (en) 1995-12-19
CZ289211B6 (cs) 2001-12-12
CN1114587A (zh) 1996-01-10
SK39195A3 (en) 1995-10-11
DE69506156T2 (de) 1999-07-22
NO951125L (no) 1995-09-29
DE69506156D1 (de) 1999-01-07
FR2717688B1 (fr) 1996-07-05
JPH07309762A (ja) 1995-11-28
ATE173617T1 (de) 1998-12-15

Similar Documents

Publication Publication Date Title
ES2127484T3 (es) Sistema matricial transdermico autoadhesivo para la administracion por via percutanea de una hormona.
ES2148178T3 (es) Uso de derivados de sulfamato como inhibidores de esteroide-sulfatasa.
ES2163444T3 (es) Composiciones y metodos para la administracion oral de farmacos.
AR003433A1 (es) Agente ectoparasiticida, procedimiento para la produccion de dicho agente uso de un compuesto contra insectos parasitos y garrapatas monofagas y para laproduccion de dicho agente.
UY25067A1 (es) Acetato de sertralina, composiciones farmacéuticas que lo contienen y procedimientos de preparación.
MX9301929A (es) Derivados de pirimidina y procedimientos para su preparacion.
DK1273289T3 (da) Farmaceutiske sammensætninger indeholdende ascomycinderivater
GT199800046A (es) Compuestos de pirazina.
KR890011601A (ko) (사이클로알킬아미노)메틸렌비스(포스폰산)및 활성성분으로서 이를 함유한 의약
ES8308213A1 (es) Procedimiento para preparar una composicion farmaceutica topica que contiene una mezcla de un agente antimicrobiano de acido graso y un corticosteroide.
SE7713341L (sv) Sett att framstella grenade och cykloalifatiska estrar ur androstan- och ostranserierna
ITMI921601A1 (it) Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci.
ES2174027T3 (es) Composiciones estables que contienen macrolidos y macrolidos combinados con unas vacunas.
AR062931A2 (es) Compuestos que se enlazan a y activan un receptor de la trombopoyetina , composicones farmaceuticas que los contienen y su uso para la preparacion de medicamentos
NO933482D0 (no) N-sulfonyl-2-oksoindol-derivater som har affinitet for vasopressin- og/eller ocytocin-reseptorer
AR017291A1 (es) Compuesto derivado de lactama, composicion farmaceutica que lo contiene y uso para tratar o prevenir diversas afecciones o enfermedades
AR012489A1 (es) Tiofenopiridinas antagonistas del factor de liberacion de corticotropina. procedimiento para su preparacion, el uso de las mismas en la preparacionde un medicamento, composicion farmaceutica que las comprende, procedimiento para la preparacion de dicha composicion, un compuesto intermediario y
ES2074294T3 (es) Derivados octapeptidicos o heptapeptidicos, su proceso de preparacion, asi como los medicamentos que los contienen y su utilizacion.
ES2179996T3 (es) Cefalosporinas de vinil-pirrolidinona con sustituyentes basicos.
NO870560L (no) Nytt farmasoeytisk preparat.
ES2114721T3 (es) Procedimiento para preparar intermedios derivados del acido benzoico y agentes farmaceuticos benzotiofenos.
NO981252L (no) Transdermalt matrikssystem
DE3866408D1 (de) Selbstklebende vorrichtung zur transdermalen verabreichung eines wirkstoffs.
DE69402114D1 (de) Neue 19-Nor-Steroide mit einer 11-Beta-Phenoxysulfonamid- oder 11-Beta-Phenoxysulfonylurea-Gruppe, Verfahren und Zwischenprodukte zu ihrer Herstellung sowie Medikamenten und pharmazeutische Präparate davon
AR035003A1 (es) Derivados de propanolamina relacionados con acidos biliares, procedimiento para su preparacion, medicamentos conteniendo estos compuestos y su empleo para la preparacion de medicamentos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 674900

Country of ref document: ES